By Karen Roman
Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) implant, in the first-in-human clinical trial of its kind.
The company also said it achieved full enrollment for this study, which targets medication adherence in metabolic diseases like chronic weight management and type 2 diabetes.
“With obesity affecting more than one billion people globally, our implants could redefine treatment paradigms by providing a convenient therapeutic alternative with significantly reduced dosing frequency compared to daily orals and weekly injectables,” said Adam Mendelsohn, Ph.D., Vivani’s CEO.
Contact:
